Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,959.00
Bid: 1,958.00
Ask: 1,960.00
Change: -41.00 (-2.05%)
Spread: 2.00 (0.102%)
Open: 2,008.00
High: 2,012.00
Low: 1,958.00
Prev. Close: 2,000.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Admiral Rises After Strong Half-Year Results

Wed, 15th Aug 2018 10:40

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------Admiral Group, up 5.0%. The motor and home insurer reported an increased interim profit driven by a good performance its UK Motor division, prompting a 7% dividend hike. Admiral posted a 9.1% increase in pretax profit to GBP211.0 million from GBP193.4 million a year before. Revenue increased 14% to GBP1.66 billion from GBP1.45 billion. Return on equity fell to 54% from 55% in the same period last year. Admiral saw an 11% profit increase in its UK Motor division, to GBP249.5 million from GBP224.2 million, in the period, mainly as a result of "growth in ancillary revenue and installment income". The company is proposing an interim dividend of 60.0 pence per share, a 7.1% increase year-on-year from 56.0p paid a year previously.----------GlaxoSmithKline, up 1.5%. The drugmaker said its majority-owned HIV specialist company ViiV Healthcare saw positive headline results from its phase III antiretroviral therapy as long-acting suppression study for the treatment of human immunodeficiency virus. Glaxo said the study showed long-acting cabotegravir and rilpivirine, injected once a month, had similar efficacy to a standard of care, daily, oral three-drug regimen at Week 48. The injectable treatment regimen met the primary endpoint for non-inferiority, Glaxo said. Overall safety, virologic response and drug resistance results for the injectable regimen were consistent with results from the phase II LATTE and LATTE-2 studies.----------FTSE 100 - LOSERS----------Fresnillo, down 2.9% and Randgold Resources, down 2.5%. The gold miners were tracking spot gold prices lower quoted at USD1,186.69 an ounce compared to USD1,196.85 at the London equities close Tuesday as the precious metal traded around its worst levels since January 2017.----------BHP Billiton, down 2.0%, Glencore, down 1.9%, Antofagasta, down 1.8%, Anglo American, down 1.7%, Rio Tinto, down 1.6%. The miners were lower amid a strengthening dollar and lower copper prices. "The price of copper has this week hit a 13-month low following a sharp slowdown in China's fixed-asset investment growth. This news, together with waning investor appetite for riskier assets, has unsurprisingly put a dent in the mining sector," said AJ Bell's Russ Mould. Midcap peer Kaz Minerals was down 3.6%.----------FTSE 250 - WINNERS----------Hikma Pharmaceuticals, up 8.5%. The drugmaker raised its annual revenue target for its Injectables and Generics divisions following a significant uplift in profit in the first half of 2018. Hikma said pretax profit for the six months to the end of June totalled USD141.0 million, up from USD100.0 million reported for the same period a year earlier, as revenue climbed 11% to USD989.0 million from USD895.0 million. On a constant currency basis, revenue rose by 10%. Hikma raised its full-year guidance for the Injectables unit and now expects revenue for 2018 to come in between USD775 million and USD825 million. Previously, Hikma targeted the Injectables division to achieve revenue growth in a range of USD750 million to USD800 million. The company declared an interim dividend of 12 cents per share, up from 11 cents paid the year before. ----------Balfour Beatty, up 3.6%. The infrastructure company reported a drop in interim revenue but increased profit, boosting its interim payout as a result. Balfour said pretax profit rose to GBP50 million from just GBP12 million the year before. Revenue decreased 9.4% to GBP3.84 billion from GBP4.20 billion. The company's underlying pretax profit increased to GBP52 million from GBP23 million. The company said a reduction in overhead costs to GBP11 million from GBP18 million led to increased profitability. Balfour is proposing an interim dividend increase of 33% to 1.6p per share from 1.2p last year. Looking ahead, the company expects its second half revenue to be in line with the first half. Balfour expects to achieve its underlying profit from operations margin targets in the second half. ----------FTSE 250 - LOSERS----------CLS Holdings, down 2.2%. The property investor reported a rise in interim net asset value as well as solid growth in net rental income for the period. Basic net asset value at the end of the period was 260.2 pence, 3.3% higher than the figure at the end of December, while EPRA net asset value was 3.0% higher at 294.7p. CLS's net rental income rose 8.7% year-on-year to GBP55.0 million, while its vacancy rate fell to 5.7% from 5.8%. Pretax profit for the period was GBP64.9 million, down year-on-year from GBP119.4 million, due to lower property valuation changes as well as the fact the comparable had a significantly higher property sale gain. Looking forward, the company said it is focusing partly on making investments in Germany and the south-east of the UK. The UK as a whole, however, is likely to remain subdued to to Brexit, but Germany and France are benefiting from strong property demand and a limit on new office space.----------OTHER MAIN MARKET AND AIM - WINNERS----------Feedback, up 22%. The medical imaging technology company said its subsidiary has secured its first order for image texture analysis technology TexRAD via GE Healthcare. Feedback said the order follows the distribution agreement, which allows medical technologies & services provider GE Healthcare non-exclusively offer TexRAD for medical imaging research applications. The new order came from the Post Graduate Institute of Medical Education & Research, located in Chandigarh, India. Feedback said its software is currently used in over 50 of the world's leading research institutions across Europe, North America, Asia and Australasia.----------
More News
29 Apr 2022 17:01

LONDON MARKET CLOSE: Stocks end volatile April on high note

(Alliance News) - Stocks in London on Friday ended a volatile month of April in a positive fashion, amid a continued rush of company earnings, while markets in the US sank as high-profile tech names disappointed.

Read more
29 Apr 2022 09:09

Hikma Pharmaceuticals notes "slow" start for Generics business in 2022

(Alliance News) - Hikma Pharmaceuticals PLC said on Friday that both its Injectables and Branded businesses have performed well at the start of the year but noted its Generics business has experienced some headwinds.

Read more
29 Apr 2022 08:32

Hikma shares fall as generics unit faces headwinds

(Sharecast News) - Hikma Pharmaceuticals shares fell as the company reported headwinds at its generics business.

Read more
29 Apr 2022 08:25

LONDON BRIEFING: Pearson has positive first quarter, buys language app

(Alliance News) - Educational materials publisher Pearson on Friday provided a positive update on first quarter trading, while also announcing a new acquisition.

Read more
21 Apr 2022 16:06

UK dividends calendar - next 7 days

Friday 22 April 
JPMorgan Global Emerging Markets Income Trust PLCdividend payment date
Henderson Eurotrust PLCdividend payment date
Monday 25 April 
abrdn Smaller Cos Income Trust PLCdividend payment date
Tuesday 26 April 
Anglo American PLCdividend payment date
Anglo American PLCspecial dividend payment date
Invesco Asia Trust PLCdividend payment date
Wednesday 27 April 
Close Brothers Group PLCdividend payment date
Thursday 28 April 
4imprint Group PLCex-dividend date
AEW UK REIT PLCex-dividend date
AVI Japan Opportunity Trust PLCex-dividend date
Bakkavor Group PLCex-dividend date
Carr's Group PLCex-dividend date
Coats Group PLCex-dividend date
CQS Natural Resources Growth & Income PLCex-dividend date
CQS New City High Yield Fund Ltdex-dividend date
Derwent London PLCex-dividend date
Drax Group PLCex-dividend date
Ecofin Global Utilities & Infrastructure Trust PLCex-dividend date
Fresnillo PLCex-dividend date
Henderson Far East Income Trust PLCex-dividend date
Hikma Pharmaceuticals PLCdividend payment date
HSBC Holdings PLCdividend payment date
Kenmare Resourcesex-dividend date
LSL Property Services PLCex-dividend date
M&G PLCdividend payment date
M P Evans Group PLCex-dividend date
Mobius Investment Trust PLCex-dividend date
Morgan Advanced Materials PLCex-dividend date
Morgan Sindall Group PLCex-dividend date
Mortgage Advice Bureau (Holdings) PLCex-dividend date
Northamber plcdividend payment date
Porvair PLCex-dividend date
Reckitt Benckiser Group PLCex-dividend date
Rightmove PLCex-dividend date
Sabre Insurance Group PLCex-dividend date
Sabre Insurance Group PLCspecial ex-dividend date
Schroder Oriental Income Fund Ltdex-dividend date
Secure Income REIT PLCex-dividend date
Smart Metering Systems PLCdividend payment date
St James's Place PLCex-dividend date
Synthomer PLCex-dividend date
Tate & Lyle PLCspecial ex-dividend date
TT Electronics PLCex-dividend date
Tyman PLCex-dividend date
XP Power Ltddividend payment date
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
21 Apr 2022 14:37

IN BRIEF: Hikma Pharmaceuticals completes Custopharm deal

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Completes acquisition of Custopharm Inc from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Back in September, Hikma agreed to buy the California-based generic injectable products company for a total of up to USD425 million. Deal will add up to 13 approved products and additional pipeline products.

Read more
20 Apr 2022 09:16

IN BRIEF: Hikma gets preliminary US approval for Custopharm acquisition

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injectable products company for a total of up to USD425 million.

Read more
20 Apr 2022 07:39

Hikma gets preliminary approval from US FTC for Custopharm deal

(Sharecast News) - Hikma Pharmaceuticals has received preliminary approval from the US Federal Trade Commission for the acquisition of sterile injectables company Custopharm Inc from Water Street Healthcare for up to $425m.

Read more
12 Apr 2022 10:11

LONDON BROKER RATINGS: JPMorgan lowers Rolls-Royce; UBS likes Ryanair

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
10 Mar 2022 16:10

UK dividends calendar - next 7 days

Friday 11 March  
Avon Protection PLCdividend payment date
Civitas Social Housing PLCdividend payment date
Impact Healthcare REIT PLCdividend payment date
Virgin Money UK PLCdividend payment date
Monday 14 March  
Tritax EuroBox PLCdividend payment date
Tuesday 15 March 
Hipgnosis Songs Fund Ltddividend payment date
Invesco Perpetual UK Smaller Cos Investment Trust PLCdividend payment date
Merchants Trust PLCdividend payment date
Wednesday 16 March  
no events scheduled 
Thursday 17 March  
Anglo American PLCex-dividend date
Anglo American PLCspecial ex-dividend date
Bellevue Healthcare Trust PLCex-dividend date
Blackrock Income & Growth Investment Trust PLCdividend payment date
BlacKRock World Mining Trust PLCex-dividend date
Brooks Macdonald Group PLCex-dividend date
Crest Nicholson Holdings PLCex-dividend date
Dunelm Group PLCex-dividend date
FW Thorpe PLCex-dividend date
FW Thorpe PLCspecial ex-dividend date
Gore Street Energy Storage Fund PLCex-dividend date
HgCapital Trust PLCex-dividend date
Hikma Pharmaceuticals PLCex-dividend date
Ideagen PLCdividend payment date
JPMorgan Mid Cap Investment Trust PLCex-dividend date
Knights Group Holdings PLCdividend payment date
M&G PLCex-dividend date
Murray Income Trust PLCdividend payment date
NatWest Group PLCex-dividend date
RM PLCex-dividend date
Segro PLCex-dividend date
Spirent Communications PLCex-dividend date
Standard Life Private Equity Trust PLCex-dividend date
Treatt PLCdividend payment date
Trifast PLCex-dividend date
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
3 Mar 2022 10:02

LONDON BROKER RATINGS: Downgrades for Hikma Pharma and Royal Mail

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
3 Mar 2022 08:28

LONDON BRIEFING: LSEG says Refinitiv savings bigger, ahead of schedule

(Alliance News) - London Stock Exchange Group on Thursday said 2021 was a successful year following the acquisition of Refinitiv, leaving the stock exchange operator well positioned as a financial market infrastructure and data business.

Read more
2 Mar 2022 09:52

LONDON BROKER RATINGS: Downgrades for AB Foods, BT and Royal Mail

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
25 Feb 2022 09:40

IN BRIEF: Hikma Pharmaceuticals launches first phase of share buyback

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Instructs Citigroup Global Markets Ltd, part of Citigroup Inc, to conduct the USD150 million first tranche of the USD300 million share buyback that it announced on Thursday. The initial phase will begin on Friday and end by June 25. Hikma had announced the buyback programme with its annual results, saying it reflected its strong cash generation, balance sheet strength, and confidence in future growth prospects. Hikma also had declared a final dividend of 36 cents, a 5.9% boost from a shareholder payout of 34 cents the year before. Its full-year dividend amounted to 54 US cents, up 8.0% from 50 cents.

Read more
25 Feb 2022 08:22

LONDON BRIEFING: IAG expects to fly 85% of pre-virus capacity in 2022

(Alliance News) - International Consolidated Airlines Group on Friday posted a narrowed loss for 2021, saying that after the setback caused by Omicron at the end of the year, bookings have rebounded strongly and it expects to fly 85% of its 2019 capacity in 2022.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.